BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 34043359)

  • 21. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
    Choi SE; Pflum MK
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
    J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
    Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
    Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
    Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
    Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities.
    Yang F; Peng S; Li Y; Su L; Peng Y; Wu J; Chen H; Liu M; Yi Z; Chen Y
    Org Biomol Chem; 2016 Feb; 14(5):1727-35. PubMed ID: 26732459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
    Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
    Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
    Wang L; Hou X; Fu H; Pan X; Xu W; Tang W; Fang H
    Bioorg Med Chem; 2015 Aug; 23(15):4364-4374. PubMed ID: 26149591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
    Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH
    Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2017 Dec; 9(18):2211-2237. PubMed ID: 29182018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
    Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
    Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
    Pan T; Dan Y; Guo D; Jiang J; Ran D; Zhang L; Tian B; Yuan J; Yu Y; Gan Z
    Eur J Med Chem; 2021 Nov; 224():113672. PubMed ID: 34237620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
    Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
    J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors: a review on class-I specific inhibition.
    Behera J; Jayaprakash V; Sinha BN
    Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
    Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
    Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.